The implementation of recently published guidelines for the management of thyroid cancer in adults should result in improved clinical outcomes for patients with this condition. A clinical biochemist should be part of the support team for the local multidisciplinary thyroid cancer management team. Serum thyroid-stimulating hormone assays should have a minimum detection limit of 0.10 mU/L or lower and good baseline security. The measurement of both thyroglobulin and calcitonin is challenging and clinical biochemists should have detailed knowledge of the performance characteristics and limitations of the assays that they report, including those referred to a specialist centre, in order to facilitate clinically valid decisions on patient management.
Introduction
In March 2002, the British Thyroid Association and the Royal College of Physicians jointly published guidelines for the management of thyroid cancer in adults. 1 Representatives of several professional bodies, including the Association of Clinical Biochemists, contributed to the guidelines development group. Subsequent publications highlighted these guidelines to physicians. 2, 3 This short article considers the implications of these guidelines for clinical biochemistry.
Thyroid cancer Incidence
Thyroid cancer is the most common endocrine malignancy, although it only represents about 1% of all malignancies. In the UK, the annual incidence is reported as 2.3 per 100 000 women and 0.9 per 100 000 men. Every year, approximately 900 new cases and 250 deaths may be attributed to thyroid cancer in England and Wales. 4
Aim of the guidelines
The prognosis for patients diagnosed with di¡erentiated thyroid cancer is generally good (80-90% survival at 10 years), especially if their management is optimal. The publication of the guidelines 1 is an important contribution to optimal management. The three main aims of the guidelines are to: improve the overall and disease-free survival of patients with thyroid cancer; enhance the health-related quality of life; and improve the referral pattern and management of patients with thyroid cancer.
Symptoms and presentation
Thyroid cancer usually presents with a lump in the neck, which may be solitary or multinodular. 5 However, thyroid nodules are common in the population (prevalence 5-10%) and usually benign. There are normally no symptoms or signs to distinguish a benign nodule from thyroid cancer. Thyroid function tests (TFTs) should be requested by the general practitioner (GP). Euthyroid patients with a thyroid nodule may have thyroid cancer and should be referred to a member of the multidisciplinary thyroid cancer team. Patients with hypo-or hyperthyroidism and a nodular goitre should be referred to an endocrinologist. Referral by the GP should be urgent if the thyroid lump is newly presenting or increasing in size, if there has been previous neck irradiation, if there is a family history of thyroid cancer, or if there are accompanying signs such as unexplained hoarseness or lymphadenopathy.
Overall management
The key recommendation in the guidelines 1 is that the management of thyroid cancer should be the Personal View responsibility of a specialist multidiscipl inary team. Members of this team will comprise a surgeon, endocrinologist and oncologist, with support from a histopathologist, medical physicist, clinical biochemist and radiologist with expertise in thyroid cancer.
Diagnosis
The initial investigation by the multidisciplinary thyroid cancer team should comprise a detailed clinical examination supported by TFTs, assessment of thyroid autoantibody status and ¢ne needle aspiration cytology (FNAC) of the thyroid lump. The diagnosis of thyroid cancer follows from the FNAC. Cancers of the follicular thyroid epithelium include papillary (*80%) and follicular (*10%) histotypes, usually referred to as`di¡erentiated thyroid carcinomas', and undi¡erentiated (or anaplastic) carcinoma (*10%). It should be noted that the pre-operative measurement of thyroglobulin (Tg) is of no diagnostic value. Cancers of the parafollicular thyroid epithelium (the C cells) are represented by medullary thyroid carcinoma (MTC), in its sporadic or hereditary form. If the results of the FNAC suggest MTC then the measurement of calcitonin and other hormones is indicated (see below). 6
Treatment
The primary treatment of di¡erentiated thyroid cancer is surgery, normally within 2 weeks of diagnosis. Total thyroidectomy is commonly performed, although lobectomy may be adequate in patients with small tumours (51 cm) that have minimally invasive features.
Most patients with tumours 41cm require radioactive iodine ( 131 I) ablation therapy (*3.7 GBq) following total thyroidectomy. Ideally, radioiodine therapy should be given by a specialist centre within 3-4 weeks of thyroidectomy. In these circumstances, there is no need for thyroid hormone replacement therapy and the serum thyroid-stimulating hormone (TSH) would be 430 mU/L at the time of radioiodine administration. Alternatively, patients should receive tri-iodothyronine (T 3 ) therapy (20 mg three times a day) following surgery, although this should be stopped 2 weeks before 131 I ablation to allow the TSH to rise above 30 mU/L. Pregnancy must be excluded before 131 I therapy is given.
Monitoring treatment
Serum calcium should be measured on the day after surgery and then daily until stable. If hypocalcaemia develops, the patient will require calcium supplementation (500 mg Ca three times a day), with or without alfacalcidol or calcitriol, and daily calcium monitoring. After total thyroidectomy about 30% of patients will require calcium supplementation, but by 3 months only about 2% of patients will still require calcium.
To minimize the risk of recurrence, treatment should include the life-long suppression of serum TSH. Thyroxine (T 4 ) is preferred to T 3 for long-term suppression, and a daily dose of 175-200 mg is normally required to maintain the serum TSH concentration below 0.10 mU/L. Thyroxine doses may be altered in increments of 25 mg, and a period of about 6 weeks must elapse after each dose adjustment before TFTs are checked. Patients in remission should have TSH checked annually.
Thyroglobulin is a useful tumour marker in patients who have had a total thyroidectomy. It is secreted by both normal and cancerous thyroid cells, so that detectable serum Tg in a patient following total thyroidectomy and 131 I ablation is highly suggestive of residual tissue or recurrent tumour and is a trigger for a diagnostic radioiodine scan. Thyroid function should be assessed at the same time as Tg since the release of Tg is TSH-dependent. Samples for Tg measurement should not be collected until at least 4-6 weeks after thyroidectomy, FNAC or radioiodine. Patients in remission should have Tg measured annually.
A diagnostic radioiodine scan (*100 MBq of 131 I) should be performed at about 6 months after thyroid ablation and also in circumstances where there is clinical or biochemical (Tg) evidence of disease progression. Before a diagnostic radioiodine scan, patients should switch from T 4 to T 3 replacement; T 4 is routinely stopped for 4 weeks and T 3 for 2 weeks before the diagnostic scan. The results of the diagnostic scan may indicate the need for further ablative therapy. Patients should restart T 4 3 days after either the diagnostic radioiodine scan or 131 I therapy.
In recent years, the use of recombinant human TSH (rhTSH) has been introduced as an alternative method to thyroid hormone withdrawal in the assessment of residual or recurrent thyroid tissue. The rhTSH (0.9 mg) is administered by deep intramuscular injection on days 1 and 2, a tracing dose of 131 I (*150 MBq) is given on day 3, and a diagnostic scan and Tg measurement are performed on day 5. A newly detectable Tg concentration or a Tg concentration rising after rhTSH are indications for further investigation. The rhTSH test o¡ers the advantage of avoiding hypothyroidism and has comparable sensitivity to thyroid hormone withdrawal in detecting functioning thyroid tissue. 7
Medullary thyroid cancer
Medullary thyroid cancer is a rare disease, accounting for about 5% of all thyroid cancers. Approximately 25% of cases of MTC are familial, with autosomal dominant inheritance as part of the syndrome of multiple endocrine neoplasia type 2 (MEN-2), so there is a need for a comprehensive and integrated approach to the patient and their family. 6 The disease is usually ¢rst diagnosed by FNAC, but unsuspected MTC can be found at surgery.
Once MTC is diagnosed, a comprehensive family history must be taken to include ¢rst-and seconddegree relatives in a search for clinical features or other endocrinopathies of the MEN-2 spectrum. Even in the absence of a positive family history or symptoms, all patients should have baseline calcitonin, catecholamines and parathyroid hormone (PTH) concentrations measured prior to treatment. Every case of MTC should normally lead to genetic testing of the patient in conjunction with the Clinical Genetics Service. Blood is examined for mutations in exons 10 and 11 and exons 13-15 of the RET proto-oncogene. If mutations are found, family members at risk should also be o¡ered testing for speci¢c RET mutations. If no mutations are found but there is presumptive evidence of inherited disease, biochemical screening of family members (aged 45 years) should be considered using the recommended calcium-pentagastrin stimulation test of calcitonin. 1 The primary treatment modality for MTC is total thyroidectomy and central node dissection. Prophylactic surgery must be considered for disease -free carriers of germ-line RET mutations. The response to therapy is monitored by measurement of the endocrine tumour marker calcitonin. Radiotherapy and chemotherapy are not normally e¡ective. Medical therapy (e.g. somatostatin analogues) may help with symptom control. Patients in remission should have calcitonin and other appropriate hormones measured annually.
The contribution of clinical biochemistry
It is clear from the above that clinical biochemistry contributes signi¢cantly to the diagnosis and management of thyroid cancer. In order that clinical biochemists are able to play their role in supporting the multidisciplinary thyroid cancer team, a number of important functions must be in place.
Thyroid function tests
Only a small proportion of the *10 million TFTs performed in the UK each year relate to thyroid cancer. However,TFTs do have an important role in enabling a speedy diagnosis and in monitoring treatment for the disease. Paradoxically, it is the ¢nding of euthyroid TFTs (both TSH and free or total T 4 ) in a patient with a lump in the neck that should encourage the GP to consider a diagnosis of thyroid cancer, and the sooner this patient is referred to the multidisciplinary thyroid cancer team, the better the clinical outcome. The measurement of TFTs is an important part of the postsurgical management of di¡erentiated thyroid cancer, with TSH being the key analyte. The assessment of adequate T 4 suppression therapy requires a TSH assay with a minimum detection limit signi¢cantly below 0.10 mU/L, and it is important that internal quality control and external quality assessment monitor the performance of the assay at this`subnormal' level because a lack of baseline security could easily lead to inappropriate management of a patient with thyroid cancer. 8
Thyroglobulin
The measurement of serum Tg is critical to the postoperative management of patients with di¡erentiated thyroid cancer because it provides the most convenient means to detect residual tissue or recurrent thyroid cancer. Unfortunately, Tg measurement is fraught with di¤culty. Analytical challenges include standardization, long-term assay stability, minimum detection limit, working range and the e¡ect of endogenous Tg antibodies (TgAb). There are signi¢cant limitations to the methods used to determine TgAb interference. These challenges have recently been reviewed in detail 9 and the main ¢ndings have been incorporated into the guidelines. 1 The increasing availability of commercial assays for Tg and TgAb may tempt clinical biochemists to provide a local service, but the analytical di¤culties in individual patient samples and the lack of external quality assessment mean that the measurement of Tg and the interpretation of Tg results should remain a specialist service for the foreseeable future.
Calcitonin, catecholamines and parathyroid hormone
The measurement of plasma calcitonin is fundamental to the diagnosis and management of MTC. 10 However, calcitonin is a small peptide, its concentration is in£uenced by diet and it is normally present in very low concentrations (515 ng/L) in plasma. Furthermore, calcitonin is unstable in vitro and fasting blood specimens must be collected into chilled tubes; the samples should be separated rapidly (530 min) and the plasma must be snap-frozen then stored and transported frozen. As a result, only a small number of specialist laboratories o¡er a calcitonin immunoassay service and there may be signi¢cant delays in turnaround time. To compound the problem, there are two di¡erent immunoassay designs in use for calcitonin measurement, with the two-site immunometric assays having an appreciably lower reference range than the traditional saturation analyses. It is clear that both attention to detail during specimen collection and the consistent use of a single referral laboratory are essential if clinically meaningful longitudinal results are to be obtained in MTC patients. 11 The interpretation of the calcitonin response to the calcium-pentagastrin stimulation test is also challenging, and clinical biochemists should seek advice from the referral laboratory that performs the analysis.
Other biochemistry tests
The measurement of calcium is important in the postoperative management of di¡erentiated thyroid cancer and in the diagnosis and management of MEN-2. It is essential to perform a pregnancy test before the administration of radioisotopes to women of reproductive years.
Genetic tests
The investigation of mutations in the RET protooncogene is now a routine part of the diagnosis of MTC and MEN-2. 12 Specialist laboratories undertake these investigations as part of the Clinical Genetics Service. Clinical biochemists may be required to advise on the availability and sample requirements of such services.
Implications of the guidelines for clinical biochemistry
The publication of the guidelines for the management of thyroid cancer in adults 1 has been widely welcomed by all those involved in the diagnosis and management of this condition. Early indications are that the recommendations in the guidelines will be implemented in many centres across the UK. Implementation of the guidelines will have implications for clinical biochemists; these responsibilities are delineated below.
First, the clinical biochemist is designated in the guidelines as a support person for the specialist multidisciplinary thyroid cancer team. Clinical biochemists across the UK should ensure that they are part of these teams, that they have a copy of the guidelines and that they are competent to provide the necessary advisory role.
Secondly, the clinical biochemistry laboratory must provide access to high quality analytical and interpretative services in accordance with the guidelines. The availability of core chemistry tests and TFTs (including a second or third generation TSH assay) may be regarded as a matter of routine. However, the clinical biochemist should also have a detailed knowledge of the performance criteria and limitations of the assays used for Tg, TgAb and calcitonin and be able to o¡er detailed interpretation of results and advice on follow-up. Such specialist knowledge may require input from experts within an external laboratory to which local specimens are referred.
Thirdly, the clinical biochemist is likely to have a key role in clinical audit of the e¡ectiveness of the guidelines at local level. This process will be facilitated if the multidisciplinary thyroid cancer team agrees detailed local protocols for the investigation of thyroid cancer that accord with the guidelines, and if data and records are kept in readily accessible ¢les.
